Efficacy and Safety of Platelet rich plasma v/s Prolotherapy in the Management of Rotator cuff tendinosis.
Not Applicable
- Conditions
- Health Condition 1: M678- Other specified disorders of synovium and tendon
- Registration Number
- CTRI/2022/05/042385
- Lead Sponsor
- AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Failure to conservative treatment for 3 months.
2.Age over 18 years and less than 75 years of age.
Exclusion Criteria
1.Underwent previous Intra-articular injection/invasive procedure.
2.Congenital or acquired platelet dysfunction.
3.Uncontrolled Diabetes Mellitus.
4.Non-consenting patient.
5.MRI contraindications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome measures will be assessed using VAS score to see patient improvement and QuickDash Score to see change in disabilityTimepoint: At baseline pre-treatment and at 1, 3, 6 and 12 weeks after the injection
- Secondary Outcome Measures
Name Time Method Safety of both the tratmentTimepoint: At each visit(1, 3, 6 and 12 weeks after the injection)